The Association of CYP2D6*4 and POR*28 Polymorphisms on Mirtazapine Plasma Level in Subjects with Major Depressive Disorder and Anxiety Disorders

Basit Öğe Kaydı
dc.authoridKir, Yagmur/0000-0002-4234-1394
dc.authoridOzdemir, Fezile/0000-0001-5463-5173
dc.authoridBASKAK, BORA/0000-0002-0723-4446
dc.authoridDural, Emrah/0000-0002-9320-8008
dc.contributor.authorOzdemir, Fezile
dc.contributor.authorDural, Emrah
dc.contributor.authorBaskak, Nilay Sedes
dc.contributor.authorKir, Yagmur
dc.contributor.authorBaskak, Bora
dc.contributor.authorSuzen, Halt S.
dc.date.accessioned2024-10-26T18:09:15Z
dc.date.available2024-10-26T18:09:15Z
dc.date.issued2020
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractAims and Objective: The plasma level of mirtazapine (MIR) varies between individuals primarily depending on the differences in metabolism during pharmacotherapy. CYP2D6 takes the role as a major enzyme in MIR metabolism and POR enzyme donates an electron to CYP2D6 for its activity. Single nucleotide polymorphisms in the genes encoding phamacokinetic enzymes may cause changes in enzyme activity, leading to differences in metabolism of the drug. Our aim was to assess the influence of CYP2D6*4 and POR*28 polymorphisms on MIR plasma levels in Turkish psychiatric patients. Materials and Methods: The association between genetic variations and plasma level of MIR was investigated on 54 patients. CYP2D6*4 and POR*28 polymorphisms were analysed using Polymerase Chain Reaction- Restriction Fragment Length Polymorphism (PCR-RFLP) and plasma MIR levels were measured using HPLC. Results: Allele frequencies of CYP2D6*4 and POR*28 were 0.11 and 0.39, respectively in the study population. The results showed that CYP2D6*4 allele carriers have higher C/D MIR levels while POR*28 allele carriers have lower C/D MIR levels. Combined genotype analyses also revealed that individuals with CYP2D6*1/*1 - POR*28/*28 genotype have a statistically lower CID MIR level (0.95 ng/ml/dose) when compared with individuals with CYP2D6*1/*1 - POR*1/*1 genotype (1.52 ng/ml/dose). Conclusion: Our results indicate that CYP2D6*4 and POR*28 polymorphisms may have a potential in the explanation of differences in plasma levels in MIR treated psychiatric patients. A combination of these variations may be beneficial in increasing drug response and decreasing adverse drug reactions in MIR psychopharmacotherapy.
dc.identifier.doi10.2174/1386207323666200402081512
dc.identifier.endpage1040
dc.identifier.issn1386-2073
dc.identifier.issn1875-5402
dc.identifier.issue10
dc.identifier.pmid32238137
dc.identifier.scopus2-s2.0-85096652027
dc.identifier.scopusqualityQ3
dc.identifier.startpage1032
dc.identifier.urihttps://doi.org/10.2174/1386207323666200402081512
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30026
dc.identifier.volume23
dc.identifier.wosWOS:000604264700006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCombinatorial Chemistry & High Throughput Screening
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMirtazapine
dc.subjectCYP2D6*4
dc.subjectPOR*28
dc.subjectplasma
dc.subjectHPLC
dc.subjectMIR psychopharmacotherapy
dc.titleThe Association of CYP2D6*4 and POR*28 Polymorphisms on Mirtazapine Plasma Level in Subjects with Major Depressive Disorder and Anxiety Disorders
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu